Who is sponsoring NCT04197180?

NCT04197180 is sponsored by Chinese University of Hong Kong.

What drugs are being tested in NCT04197180?

Interventions in NCT04197180: Hybrid Argon Plasma Coagulation.

What condition does NCT04197180 study?

NCT04197180 studies Gastric Low Grade Intraepithelial Neoplasia.

Is NCT04197180 still recruiting?

NCT04197180 is currently status unknown. Last updated 7 November 2023.

Last reviewed 2023-11-07 · How we verify

NCT04197180: HybridAPC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Hybrid APC for Gastric Low Grade Intraepithelial Neoplasia

Status unknown NA Last updated 7 November 2023

What this trial tests

NA trial testing Hybrid Argon Plasma Coagulation in Gastric Low Grade Intraepithelial Neoplasia in 100 participants. Status unknown.

Timeline

1 March 2020

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Chinese University of Hong Kong
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 March 2020
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across Hong Kong

Drugs / interventions tested

Hybrid Argon Plasma Coagulation

Conditions studied

Gastric Low Grade Intraepithelial Neoplasia — all drugs for Gastric Low Grade Intraepithelial Neoplasia →

Sponsor

Chinese University of Hong Kong

Who can join

Adults 18 to 85, any sex, with Gastric Low Grade Intraepithelial Neoplasia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This cohort study aims to investigate the clinical efficacy and safety of Hybrid APC for treatment of gastric low grade intramucosal neoplasia.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Gas Plasma Combination Therapies-Promises from Preclinical Oncology Research.
Yu L, Berner J, Martinet A, Freund E, et al · · 2025 · PMID 41008962 · DOI 10.3390/antiox14091055

Verify or expand the search:

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

NCT07508644 — RSV Vaccination to Reduce Recurrent AECOPD · Phase 4 · not yet recruiting
NCT07230457 — Plasma MTB cfDNA Before Bronchoscopy · not yet recruiting
NCT07288671 — Nostalgia Intervention on Alleviating Loneliness Amongst Older Adults · NA · not yet recruiting
NCT07256457 — Postoperative Pulmonary Function Assessment Based on Deep Learning Study · NA · not yet recruiting
NCT06904209 — Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04197180 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chinese University of Hong Kong
Last refreshed: 7 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04197180.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing